Categories:
![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-118.jpg)
WHO publishes draft about health product traceability policies
The World Health Organization (WHO) has published a draft about health product traceability policies
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-102.jpg)
ANVISA – Compliance of similar medicines
Anvisa issues Service Orientation N°79/GGMED/DIRE2/ANVISA, of January 29, 2020 and one Information
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/cofepris.png)
COFEPRIS – Recognition of Marketing Authorizations from Reference Authorities – updated 18th March
On January 28, 2020, an Agreement from the Mexican Comisión Federal para la Protección Contra Ries
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-103.jpg)
ANVISA – Proposal for new Bioavailability/ Bioequivalence (BA/BE) Studies
On January 2, 2020 ANVISA published in the Brazil the Public Consultation Nº 760 which provides on
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-115.png)
EMA – Pilot programme for international cooperation in GMP inspection of manufacturers of sterile medicinal products for human use
The European Medicines Agency (EMA) and its European and international partners launched a pilot pro
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-116.png)
INFARMED – Economic Evaluation by INFARMED
With two publications on December 16, Infarmed informs the public about measures taken in support of
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/fig2.jpg)
ICH News
The International Harmonization Council (ICH) met in Singapore from 16 to 20 November 2019, bringing
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-117.jpg)
Update in Drug Regulation in China – Revocation of GMPc Requirements
On August 26, 2019, the Standing Committee of the National People’s Congress of China passed the A
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2019/11/2022.05.09-Nitrosaminas_EN.jpg)
Nitrosamine Medicinal Products Contamination – Scenario in Europe, United States, and Latin America – updated on July 19, 2023
In 2018, nitrosamine impurities, including N-nitrosodimethylamine (NDMA), were found in several bloo
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-105.jpg)
ANVISA – Traceability/Serialization
After ten years of extensive debate, since the enactment of Law 11.903 / 2009, on November 13th, RDC
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-106.jpg)
New Regulation for Stability Studies of Medicinal Products and APIs in Brazil – Resolution RDC 318/2019
On November 7, 2019, ANVISA published the Resolution RDC 318/2019, which defines the criteria for co
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-111.jpg)
Importation procedures in Mexico – Mexican Foreign Trade Receipt System (Ventanilla Única de Comercio Exterior Mexicano – VUCEM)
The Mexican Foreign Trade Receipt System (VUCEM) is an integral service platform that facilitates ac
Ler mais